Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Non Operating Income (2020 - 2025)

Lyell Immunopharma's Non Operating Income history spans 5 years, with the latest figure at -$1.6 million for Q3 2025.

  • For Q3 2025, Non Operating Income fell 3604.65% year-over-year to -$1.6 million; the TTM value through Sep 2025 reached -$958000.0, up 71.56%, while the annual FY2024 figure was $4.7 million, 154.28% up from the prior year.
  • Non Operating Income for Q3 2025 was -$1.6 million at Lyell Immunopharma, down from $1.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.4 million in Q4 2022 and bottomed at -$35.3 million in Q4 2021.
  • The 5-year median for Non Operating Income is -$14000.0 (2022), against an average of -$1.6 million.
  • The largest annual shift saw Non Operating Income crashed 23956.25% in 2022 before it soared 37078.57% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$35.3 million in 2021, then surged by 118.08% to $6.4 million in 2022, then crashed by 161.88% to -$4.0 million in 2023, then surged by 53.06% to -$1.9 million in 2024, then rose by 14.12% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Non Operating Income are -$1.6 million (Q3 2025), $1.2 million (Q2 2025), and $1.3 million (Q1 2025).